Abstract
On Saturday 1 September a Satellite symposium was organised by Merck/Shering-Plough (MSP) and chaired by G. Maurer (Vienna, Austria) and J.J.P. Kastelein (Amsterdam, the Netherlands), on the additive value of cholesterol absorption inhibitors to achieve low-density lipoprotein cholesterol (LDL-C) levels below 70 mg/dl (<1.81 mmol/l). Recent upgraded guidelines from the ESC and the EASD include an LDL-C below 70 mg/dl for secondary prevention of cardiovascular (CV) events in diabetic patients with symptomatic cardiovascular disease (CVD). In many European countries the current guideline target levels of an LDL-C of <100 mg/dl (<2.5 mmol/l) are reached in less than 40% of treated patients, with a large portion of patients even remRoleing untreated.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Isala Clinics, location Wezenland, Zwolle, the Netherlands,
Rights and permissions
About this article
Cite this article
Maas, A.H.E.M. The bridge to achieving the greater LDL-C goal of <70 mg/dl: inhibiting cholesterol absorption and production. NHJL 15, 14 (2007). https://doi.org/10.1007/BF03086053
Issue Date:
DOI: https://doi.org/10.1007/BF03086053